Minimising chemotherapy while optimising immune therapy for paediatric nodular lymphocyte-predominant Hodgkin's lymphoma

Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) is a rare but distinct subtype of Hodgkin's lymphoma (HL) that carries a better prognosis than classical Hodgkin's lymphoma. Historically, both subtypes of Hodgkin's lymphomas (classical HL and NLPHL) have been grouped together and treated as classical Hodgkin's lymphoma. Recent studies have questioned this approach and have called for an alternative method due to expected severe long-term adverse events. We report two cases of NLPHL that were successfully treated with reduced chemotherapy cycles, as well as rituximab, in the form of R-CHOP (rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone).